Alnylam Pharmaceuticals | ALNY - Sales Revenues

Stock Price
304.61
Daily Change
-3.90 -1.26%
Monthly
-3.63%
Yearly
18.44%
Q2 Forecast
299.00

Alnylam Pharmaceuticals reported $1.1B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.11B 750M Mar/2026
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.14B 65M Mar/2026
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025